EigerBio Europe

EigerBio Europe is a commercial-stage biopharmaceutical company focused on developing innovative therapies to treat and cure hepatitis virus (HDV) and other serious rare diseases. The company concentrates on the development and commercialization of targeted therapies for severe rare and ultra-rare diseases. It is committed to delivering vital medications to patients in need more quickly by developing well-characterized drugs that target newly discovered or novel mechanisms. EigerBio Europe has identified the therapeutic potential of untapped molecules with well-established safety profiles, aiming to develop treatments for life-threatening conditions that currently have no approved therapies.